201 related articles for article (PubMed ID: 20930099)
21. A drug safety evaluation of rituximab and risk of hepatitis B.
Riedell P; Carson KR
Expert Opin Drug Saf; 2014 Jul; 13(7):977-87. PubMed ID: 24821316
[TBL] [Abstract][Full Text] [Related]
22. Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis.
Ghrénassia E; Mékinian A; Rouaghe S; Ganne N; Fain O
Joint Bone Spine; 2012 Jan; 79(1):100-1. PubMed ID: 21944979
[No Abstract] [Full Text] [Related]
23. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient.
Feeney SA; McCaughey C; Watt AP; Agnaf MR; McDougall N; Wend UC; Gerlich WH; Coyle PV
J Med Virol; 2013 Apr; 85(4):597-601. PubMed ID: 23359331
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis B virus reactivation in a primary central nervous system lymphoma patient following intrathecal rituximab treatment.
Kim MG; Park SY; Kim EJ; Kim YM; Kim HY; Lee YK; Zang DY; Kim HJ
Acta Haematol; 2011; 125(3):121-4. PubMed ID: 21150178
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment.
Voican CS; Mir O; Loulergue P; Dhooge M; Brezault C; Dréanic J; Chaussade S; Pol S; Coriat R
Ann Oncol; 2016 Dec; 27(12):2172-2184. PubMed ID: 27803003
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis B re-activation with rituximab therapy: treat the patient not the disease.
Zachou K; Dalekos GN
Liver Int; 2011 Mar; 31(3):277-9. PubMed ID: 21281426
[No Abstract] [Full Text] [Related]
27. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.
Tsutsumi Y; Kawamura T; Saitoh S; Yamada M; Obara S; Miura T; Kanamori H; Tanaka J; Asaka M; Imamura M; Masauzi N
Leuk Lymphoma; 2004 Mar; 45(3):627-9. PubMed ID: 15160930
[TBL] [Abstract][Full Text] [Related]
28. Fatal reactivation of occult hepatitis B virus infection after rituximab and chemotherapy in lymphoma: necessity of antiviral prophylaxis.
Zhang B; Wang J; Xu W; Wang L; Ni W
Onkologie; 2010; 33(10):537-9. PubMed ID: 20926902
[TBL] [Abstract][Full Text] [Related]
29. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy.
Chen XQ; Peng JW; Lin GN; Li M; Xia ZJ
Med Oncol; 2012 Jun; 29(2):1237-41. PubMed ID: 21556931
[TBL] [Abstract][Full Text] [Related]
30. Reactivation of hepatitis virus B infection in a patient with rheumatoid arthritis after treatment with rituximab.
Salman-Monte TC; Lisbona MP; García-Retortillo M; Maymó J
Reumatol Clin; 2014; 10(3):196-7. PubMed ID: 24054835
[No Abstract] [Full Text] [Related]
31. Efficient Prophylactic Management of HBV Reactivation by an Information Technology Encoding System: Results of a 6-year Prospective Cohort Study.
Notsumata K; Nomura Y; Tanaka A; Nomura Y; Ueda T; Sanada T; Watanabe H; Toya D
Intern Med; 2020; 59(20):2457-2464. PubMed ID: 33055468
[TBL] [Abstract][Full Text] [Related]
32. [Hepatitis B virus reactivation in rituximab-treated patients: incidence and risk factors].
Gutiérrez García ML; Alonso Lopez S; Martín Rios MD; Sanmartin Fenollera P; Agudo Fernandez S; Fernández Rodriguez CM
Gastroenterol Hepatol; 2015 Jan; 38(1):1-6. PubMed ID: 25205080
[TBL] [Abstract][Full Text] [Related]
33. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.
Perceau G; Diris N; Estines O; Derancourt C; Lévy S; Bernard P
Br J Dermatol; 2006 Nov; 155(5):1053-6. PubMed ID: 17034541
[TBL] [Abstract][Full Text] [Related]
34. [Impending liver failure after chemoimmunotherapy-induced reactivation of hepatitis B - successful treatment with entecavir].
Lock G; Helmich F; Bertram M
Dtsch Med Wochenschr; 2012 Jun; 137(23):1248-50. PubMed ID: 22644491
[TBL] [Abstract][Full Text] [Related]
35. [Risk of reactivation of hepatitis B in patients with the lymphoma HBsAg negative , anti-HBc positive treated with rituximab-CHOP].
Pariente A
Rev Prat; 2014 Mar; 64(3):324. PubMed ID: 24851363
[No Abstract] [Full Text] [Related]
36. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.
Viganò M; Mangia G; Lampertico P
Expert Opin Biol Ther; 2014 Jul; 14(7):1019-31. PubMed ID: 24909454
[TBL] [Abstract][Full Text] [Related]
37. Strategy for preventing hepatitis B reactivation in patients with resolved hepatitis B virus infection after rituximab-containing chemotherapy.
Kusumoto S; Tanaka Y; Mizokami M; Ueda R
Hepatology; 2014 Aug; 60(2):765-6. PubMed ID: 24347499
[No Abstract] [Full Text] [Related]
38. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy.
Niscola P; Del Principe MI; Maurillo L; Venditti A; Buccisano F; Piccioni D; Amadori S; Del Poeta G
Leukemia; 2005 Oct; 19(10):1840-1. PubMed ID: 16094417
[No Abstract] [Full Text] [Related]
39. Rituximab and hepatitis B reactivation in HBsAg-negative/ anti-HBc-positive kidney transplant recipients.
Lee J; Park JY; Huh KH; Kim BS; Kim MS; Kim SI; Ahn SH; Kim YS
Nephrol Dial Transplant; 2017 Apr; 32(4):722-729. PubMed ID: 28339910
[TBL] [Abstract][Full Text] [Related]
40. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
Kusumoto S; Arcaini L; Hong X; Jin J; Kim WS; Kwong YL; Peters MG; Tanaka Y; Zelenetz AD; Kuriki H; Fingerle-Rowson G; Nielsen T; Ueda E; Piper-Lepoutre H; Sellam G; Tobinai K
Blood; 2019 Jan; 133(2):137-146. PubMed ID: 30341058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]